Tilray Brands (NASDAQ:TLRY) Stock Price Up 8.1% – Time to Buy?

Tilray Brands, Inc. (NASDAQ:TLRY)’s stock price rose 8.1% during trading on Tuesday . The company traded as high as $4.78 and last traded at $4.78. Approximately 5,542,429 shares changed hands during trading, an increase of 28% from the average daily volume of 4,335,643 shares. The stock had previously closed at $4.42.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Cannabis-sector takeover speculation: Curaleaf’s reported plan to pursue Aurora Cannabis prompted renewed interest in cannabis equities, supporting TLRY’s move higher. Tilray Brands stock rises as Curaleaf plots hostile takeover for Aurora
• Positive Sentiment: Hi*Ball expands in the U.K.: Tilray’s zero-sugar energy brand became the Official Energy Drink Partner of Wolverhampton Wanderers for the upcoming English Football League Championship season. The partnership should increase brand visibility and consumer access in the U.K., although its near-term financial impact is uncertain. Hi*Ball Energy partnership with Wolverhampton Wanderers
• Positive Sentiment: New beverage launches: Breckenridge Distillery introduced Peach Whiskey, adding a locally sourced flavored product to Tilray’s craft spirits portfolio and broadening its consumer packaged goods offering. Breckenridge Peach Whiskey launch
• Positive Sentiment: Revenue growth outlook: Tilray is targeting approximately $1 billion in annual revenue after reporting 11% fiscal-year growth. Management points to international cannabis opportunities and U.S. craft beer as potential growth drivers. Tilray targets $1 billion in annual revenue
• Neutral Sentiment: BrewDog marketing campaign: Tilray-owned BrewDog launched “Park IPA,” supported by advertising, retail promotions, Deliveroo sampling and bar vouchers in London. The campaign may improve seasonal brand engagement, but its effect on consolidated results is not yet clear. BrewDog launches Park IPA campaign
• Negative Sentiment: Terrapin brewery closure: Tilray plans to cease brewing at its Terrapin site in Georgia and shift production to other network breweries. The move could improve efficiency, but it also signals restructuring and potential disruption or impairment costs. Tilray to cease brewing at Terrapin site

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Weiss Ratings cut Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Wall Street Zen downgraded Tilray Brands from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. TD Cowen decreased their price target on Tilray Brands from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Finally, TD Securities raised Tilray Brands to a “strong-buy” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tilray Brands currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Tilray Brands Price Performance

The stock’s fifty day moving average price is $4.56 and its 200-day moving average price is $6.03. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.21 and a quick ratio of 1.37. The firm has a market cap of $651.04 million, a price-to-earnings ratio of -4.43 and a beta of 1.90.

Tilray Brands (NASDAQ:TLRY) last issued its quarterly earnings results on Tuesday, July 28th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.42). Tilray Brands had a negative net margin of 13.11% and a negative return on equity of 7.76%. The firm had revenue of $281.71 million during the quarter, compared to analysts’ expectations of $246.30 million. Equities research analysts predict that Tilray Brands, Inc. will post -0.4 EPS for the current fiscal year.

Insider Activity

In other Tilray Brands news, CFO Carl A. Merton bought 10,000 shares of Tilray Brands stock in a transaction dated Tuesday, August 4th. The stock was bought at an average price of $4.62 per share, for a total transaction of $46,200.00. Following the completion of the acquisition, the chief financial officer directly owned 139,753 shares of the company’s stock, valued at approximately $645,658.86. This trade represents a 7.71% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 15,000 shares of company stock valued at $69,225 in the last ninety days. 0.84% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Hilton Head Capital Partners LLC acquired a new stake in Tilray Brands during the 4th quarter worth about $38,000. Essential Partners LLC increased its holdings in shares of Tilray Brands by 110,137.5% in the 1st quarter. Essential Partners LLC now owns 8,819 shares of the company’s stock valued at $57,000 after purchasing an additional 8,811 shares during the period. Deutsche Bank AG purchased a new stake in shares of Tilray Brands in the second quarter worth approximately $44,000. Engineers Gate Manager LP purchased a new stake in shares of Tilray Brands in the fourth quarter worth approximately $126,000. Finally, R Squared Ltd acquired a new stake in shares of Tilray Brands during the first quarter worth approximately $94,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.